New combo shot targets stomach cancer belly fluid
NCT ID NCT06759064
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether injecting two drugs directly into the belly can help control fluid buildup (ascites) caused by stomach cancer. The drugs are sintilimab, which helps the immune system fight cancer, and zoledronic acid, which may slow cancer growth. The trial involves 24 adults with advanced stomach cancer and aims to find a safe dose and see if it shrinks the fluid.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sintilimab (immune checkpoint inhibitor) plus zoledronic acid
What this could lead to
If it works, this could offer a new way to control malignant ascites in gastric cancer, potentially improving comfort and survival.
What could go wrong
This is an early phase I/II trial with only 24 participants, so results may not apply broadly. Side effects from the drug combination could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASCITES, MALIGNANT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Qilu Hospital of Shandong University
RECRUITINGJinan, Shandong, 250012, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••